Newsletter | 01 February 2002 Access News 6, Focus on Malaria, February 2002 HIV/AIDS INTELLECTUAL PROPERTY AND TRADE MALARIA TROPICAL & NEGLECTED DISEASES VACCINES How much for an effective malaria treatment is the focus of this edition, as well as MSF in Burundi, Doha and a potential breakthrough, trapped in the ACCESS crisis, life with chagas and HIV and meningitis outbreaks. Read, watch, share Filter by - Any -BlogEventsFeature storyInterviewIssue briefLetterNewsletterOpinion articlePhoto storyPress releaseReportReport seriesResearch articleSpeechStatementTechnical briefVideo Statement | 30 April 2014 Intellectual property and trade India MSF responds to US Trade 301 Watch List 2 min Press release Press release | 10 December 2013 HIV/AIDS MSF calls for scale-up of ‘viral load’ monitoring to improve HIV treatment outcomes in developing countries 4 min Issue brief | 06 December 2013 HIV/AIDS HIV status? Undetectable Press release | 02 December 2013 HIV/AIDS Intellectual property and trade Tuberculosis Proposed shake-up to drug pricing framework risks middle-income countries paying more Video Video | 29 November 2013 HIV/AIDS HIV status: Undetectable Press release | 25 November 2013 HIV/AIDS Millions Still Waiting For AIDS Revolution Events | 19 November 2013 HIV/AIDS HIV Co-infections in India - When ARVs alone may not be enough Press release | 13 August 2013 HIV/AIDS As US FDA approves promising new HIV drug dolutegravir, MSF asks when people in developing countries will have access Load More
Statement | 30 April 2014 Intellectual property and trade India MSF responds to US Trade 301 Watch List 2 min
Press release Press release | 10 December 2013 HIV/AIDS MSF calls for scale-up of ‘viral load’ monitoring to improve HIV treatment outcomes in developing countries 4 min
Press release | 02 December 2013 HIV/AIDS Intellectual property and trade Tuberculosis Proposed shake-up to drug pricing framework risks middle-income countries paying more
Press release | 13 August 2013 HIV/AIDS As US FDA approves promising new HIV drug dolutegravir, MSF asks when people in developing countries will have access
